2018
A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution.
Pumpalova Y, Kozak M, von Eyben R, Kunz P, Fisher G, Chang D, Haraldsdottir S. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution. Journal Of Clinical Oncology 2018, 36: e15573-e15573. DOI: 10.1200/jco.2018.36.15_suppl.e15573.Peer-Reviewed Original ResearchA randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Kunz P, Catalano P, Nimeiri H, Fisher G, Longacre T, Suarez C, Yao J, Kulke M, Hendifar A, Shanks J, Shah M, Zalupski M, Schmulbach E, Reidy D, Strosberg J, O'Dwyer P, Benson A. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal Of Clinical Oncology 2018, 36: 4004-4004. DOI: 10.1200/jco.2018.36.15_suppl.4004.Peer-Reviewed Original Research
2015
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Kunz P, Catalano P, Nimeiri H, Fisher G, Longacre T, Schrijver I, Reidy D, Strosberg J, O'Dwyer P, Benson A. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal Of Clinical Oncology 2015, 33: tps4145-tps4145. DOI: 10.1200/jco.2015.33.15_suppl.tps4145.Peer-Reviewed Original Research
2012
Capecitabine-Induced Chest Pain Relieved by Diltiazem
Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-Induced Chest Pain Relieved by Diltiazem. The American Journal Of Cardiology 2012, 110: 1623-1626. PMID: 22939579, DOI: 10.1016/j.amjcard.2012.07.026.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAntimetabolites, AntineoplasticAnus NeoplasmsCalcium Channel BlockersCapecitabineCarcinoma, Squamous CellChest PainColorectal NeoplasmsCoronary VasospasmDeoxycytidineDiltiazemElectrocardiographyFemaleFluorouracilFollow-Up StudiesHumansMaleMiddle AgedProdrugsSecondary PreventionTreatment OutcomeConceptsChest painAcute ST-segment elevation myocardial infarctionST-segment elevation myocardial infarctionAnal squamous cell carcinomaSignificant coronary artery diseaseDiscontinuation of capecitabineElevation myocardial infarctionCoronary artery diseasePrimary colorectal adenocarcinomaSquamous cell carcinomaIschemia evaluationSecondary prophylaxisTroponin elevationArtery diseaseInitial presentationSustained reliefElectrocardiographic findingsCell carcinomaMyocardial infarctionColorectal adenocarcinomaPainPatientsChemotherapeutic agentsNovel management strategiesCapecitabine
2010
A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.
Kunz P, Kuo T, Zahn J, Kaiser H, Norton J, Visser B, Longacre T, Ford J, Balise R, Fisher G. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. Journal Of Clinical Oncology 2010, 28: 4104-4104. DOI: 10.1200/jco.2010.28.15_suppl.4104.Peer-Reviewed Original Research
2008
Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer
Cabebe E, Kuo T, Koong A, Welton M, Shelton A, Kunz P, Ford J, Sikic B, Kaiser H, Rogers J, Fisher G. Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer. Journal Of Clinical Oncology 2008, 26: 15019-15019. DOI: 10.1200/jco.2008.26.15_suppl.15019.Peer-Reviewed Original ResearchA phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results
Kunz P, Kuo T, Kaiser H, Norton J, Longacre T, Ford J, Fisher G. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results. Journal Of Clinical Oncology 2008, 26: 15502-15502. DOI: 10.1200/jco.2008.26.15_suppl.15502.Peer-Reviewed Original Research